Company Information
USD
15.22
- (-2.1%)
NASDAQ:MGNX, MACROGENICS, INC.
Industry: Biotechnology
End of Day: 2 May 2024 GMT-4
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.
Address
9704 Medical Center Drive
Website
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Dr. Margaret A. Liu, M.D.
Director
Ms. Meenu Chhabra Karson
Director
Dr. David C. Stump,M.D.
Director
Mr. William K. Heiden
Chairman of the Board/Director
Mr. Edward M. Hurwitz, J.D.
Director
Mr. Scott T. Jackson
Director
Dr. Ezio Bonvini, M.D.
Chief Scientific Officer/Senior VP, Divisional
Ms. Lynn Cilinski
Chief Accounting Officer/Controller/Treasurer/Vice President
Dr. Scott Koenig, M.D.,PhD
CEO/Co-Founder/Director/President
Mr. James Karrels
CFO/Secretary/Senior VP
Mr. Eric Risser
COO
Dr. Karen Jean Ferrante
Director
Dr. Stephen L. Eck
Chief Medical Officer/Senior VP, Divisional
Mr. Thomas Spitznagel
Senior VP, Divisional
Mr. Jeffrey Stuart Peters
General Counsel/Other Corporate Officer/Senior VP
Dr. Jay Siegel, M.D.
Director
Ms. Federica O'Brien
Director
Ownership
Institution Holdings
Bellevue Group AG
9,953,313 (16.046%)
Bellevue Asset Management AG
9,809,913 (15.815%)
BB Biotech AG
8,929,963 (14.396%)
BlackRock Inc
6,140,349 (9.899%)
T. Rowe Price Investment Management,Inc.
5,639,994 (9.092%)
Armistice Capital, LLC
4,572,000 (7.371%)
Vanguard Group Inc
4,309,394 (6.947%)
RA Capital Management, LLC
4,053,077 (6.534%)
RA Capital Management, LP
4,053,077 (6.534%)
T. Rowe Price
3,016,272 (4.863%)
Individual Holdings
Dr. Scott Koenig, M.D.,PhD
1,077,628 (1.737%)
Mr. James Karrels
171,452 (0.276%)
Dr. Ezio Bonvini, M.D.
100,892 (0.163%)
Mr. Eric Risser
38,900 (0.063%)
Mr. Edward M. Hurwitz, J.D.
33,074 (0.053%)
Dr. Stephen L. Eck
9,798 (0.016%)
Mr. Jeffrey Stuart Peters
8,895 (0.014%)
Mr. Thomas Spitznagel
8,316 (0.013%)
Ms. Lynn Cilinski
6,213 (0.010%)
Funds Holdings
BB Biotech AG
9,779,963 (15.767%)
T. Rowe Price Small-Cap Value Fund
1,646,300 (2.654%)
iShares Russell 2000 ETF
1,477,432 (2.382%)
T. Rowe Price Small-Cap Stock Fund
1,372,461 (2.213%)
T. Rowe Price US Small-Cap Core Equity
1,372,461 (2.213%)
Vanguard Institutional Extnd Mkt Idx Tr
904,994 (1.459%)
Wasatch Ultra Growth Fund
890,602 (1.436%)
SPDR® S&P Biotech ETF
889,501 (1.434%)
T. Rowe Price U.S. Small-Cap Value Eq Tr
786,992 (1.269%)
T. Rowe Price U.S. Small-Cap Core Eq Tr
670,705 (1.081%)
Make Smart Investment Choices
8BIT Global Pte Ltd.
1557 Keppel Road, #01-01
Singapore 089066
Singapore 089066
